In solid tumor trials, Kreitman et al. [168], conducted a phase I trial (NCT00006981) to evaluate SS1P (an anti-mesothelin PE-based rIT) given by continuous infusion in chemoresistant mesothelin-expressing mesothelioma, ovarian, or pancreatic cancers. This evidence concerns the gene MSLN and familial pancreatic carcinoma.